A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2018
At a glance
- Drugs AZD 5718 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 05 Feb 2018 Planned End Date changed from 21 May 2018 to 31 May 2018.
- 05 Feb 2018 Planned primary completion date changed from 21 May 2018 to 31 May 2018.
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.